A Phase 3 interventional study of CAB OLI and CAB LA in HIV Infections, sponsored by ViiV Healthcare. Completed at 18 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-05.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.
Among the 36 studies testing cabotegravir in HIV Infections, this one is the 12th largest by enrollment, is one of 6 that started in 2020, is one of 12 in phase 3, and was the 20th registered.
4,736 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in South Africa
Ages up to 10 days · Healthy volunteers
Africa Health Research Institute · Sites in South Africa
Ages 15–30 · Healthy volunteers
Evandro Chagas National Institute of Infectious Disease · Sites in Brazil
Ages 18–30 · Men only · Healthy volunteers
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2008; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 437 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 200 across the 36 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 36 have an industry lead sponsor. The 7 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 30th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2020, is one of 65 in phase 3, and was the 210th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing cabotegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06786520ViiV HealthcareA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults | 2027-03-08 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies testing cabotegravir in HIV Infections, from their registry updates:
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
The overall objective of the CAB LA + RPV LA clinical development program is to develop a highly effective, well-tolerated, two-drug, LA injectable regimen which has the potential to offer improved treatment convenience, compliance and improved quality of life for people living with HIV compared to current standard of care. This interventional study will examine different implementation strategies in different clinic settings across European countries to identify strategies which best meet the needs in each local context and involve both participants receiving study treatment CAB LA + RPV LA (patient study participants [PSP]) as well as the healthcare providers at the investigator site level (staff study participants [SSP]). SSPs consists of 2 groups: standard and enhanced arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin [hCG] test at screen and at Day 1), not lactating, and at least one of the following conditions applies:
Non- is defined as:
Pre-menopausal females with one of the following:
Exclusion criteria:
Evidence of virus (HBV) infection based on the results of testing for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV Deoxyribonucleic acid (DNA) as follows:
Participants with HCV co-infection will be allowed entry into this study if:
In the event that recent biopsy or imaging data is not available or inconclusive, the Fib-4 score will be used to verify eligibility:
(Age times [AST]) / ( times (square [Alanine aminotransferase]{ALT}).
Treatment with any of the following agents within 28 days of Day 1:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV-infected participants will receive CAB LA + RPV LA regimen for a month of oral lead in (OLI) at Day 1 followed by CAB LA + RPV LA injections at Months 1 and 2 and every 2 months (Q2M) thereafter.
Drug: CAB OLI · Drug: CAB LA · Drug: RPV OLI · Drug: RPV LA
Staff study participants will be randomized to receive standard implementation support (Arm-S; through visit(s) with the medication lead in their country, education on the medication, and patient and staff education/support materials) or through enhanced implementation support (Arm-E; through the addition of continuous quality improvement during the study).
Other: Continuous Quality Improvement (CQI) calls
CAB will be available as 30 milligrams (mg) tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
CAB LA 600 mg will be administered as intramuscular (IM) injection.
RPV will be available as 25 mg tablet. It will be administered as one tablet once daily with food from Day 1 to Month 1.
RPV LA 900 mg will be administered as IM injection.
CQI will be attended by the enhanced arm (Arm-E). The CQI calls will be conducted to identify problems/challenges, generate plans to address the challenges, and identify how to measure the change that results from the plan.
Change From Baseline in Acceptability of Implementation Measure (AIM-Imp) Score in SSP at Month 12
The AIM-Imp was designed to assess the acceptability of an implementation process (i.e., perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory). The measure consists of four items/statements (1. The implementation support thus far meets my approval 2. The implementation support thus far is appealing to me 3. I like the implementation support I have received 4. I welcome implementation support for the CAB + RPV injection treatment), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.
Time frame: Baseline (Month 1) and Month 12
Change From Baseline in Implementation Appropriateness Measure (IAM-Imp) Score in SSPs at Month 12
The IAM-Imp is designed to assess the appropriateness of an implementation process (i.e., the perceived fit, relevance, or compatibility of the innovation for a given practice setting, provider, or consumer, and the perceived fit of the innovation to address a particular issue or problem). The IAM-Imp is a four-item/statement measure (1. The implementation support thus far seems fitting 2. The implementation support seems suitable for using the CAB + RPV injection treatment 3. The implementation support seems applicable for the CAB + RPV injection treatment 4. The implementation support seems like a good match) with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least appropriateness and 5 the most appropriateness.
Time frame: Baseline (Month 1) and Month 12
Change From Baseline in Feasibility of Implementation Measure (FIM-Imp) Score at Month 12
The FIM-Imp was a four-item/statement measure (1. The implementation support seems implementable in our clinic/practice 2. The implementation support seems possible in our clinic/practice 3. The implementation support seems doable in our clinic/practice 4. The implementation support seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.
Time frame: Baseline (Month 1) and Month 12
Number of Participants That Discussed Themes Arising Out of Qualitative Semi-structured Interviews Which Are Coded as Acceptability
A semi-structured interview guide was designed to support the discussion surrounding experience with the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the acceptability from the SSPs' perspective. The results of themes that are integral to successful implementation are presented based on implementation strategies.
Time frame: Up to 12 Months
Number of Participants That Discussed Themes Arising Out of Qualitative Semi-structured Interviews Which Are Coded as Appropriateness
A semi-structured interview guide was designed to support the discussion surrounding experience with the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the appropriateness from the SSPs' perspective. The results of themes that are integral to successful implementation are presented based on implementation strategies.
Time frame: Up to Month 12
Number of Participants That Discussed Themes Arising Out of Qualitative Semi-structured Interviews Which Are Coded as Feasibility
A semi-structured interview guide was designed to support the discussion surrounding experience with the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the feasibility from the SSPs' perspective. The results of themes that are integral to successful implementation are presented based on implementation strategies.
Time frame: Up to Month 12
Number of Staff Study Participants That Discussed Facilitators for Acceptability Assessed Via Semi Structured Interviews (SSIs)
A semi-structured interview guide was designed to support the discussion surrounding experience with the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the acceptability from the SSPs' perspective. The results for facilitators that are integral to successful implementation are presented.
Time frame: Up to 12 Months
Number of Staff Study Participants That Discussed Barriers for Acceptability Assessed Via SSIs
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the acceptability from the SSPs' perspective. The results for barriers that are integral to successful implementation are presented.
Time frame: Up to 12 Months
Number of Staff Study Participants That Discussed Facilitators for Appropriateness Assessed Via SSIs
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the appropriateness from the SSPs' perspective. The results for facilitators that are integral to successful implementation are presented.
Time frame: Up to 12 Months
Number of Staff Study Participants That Discussed Barriers for Appropriateness Assessed Via SSIs
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the appropriateness from the SSPs' perspective. The results for barriers that are integral to successful implementation are presented.
Time frame: Up to 12 Months
Number of Staff Study Participants That Discussed Facilitators for Feasibility Assessed Via SSIs
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the feasibility from the SSPs' perspective. The results for facilitators that are integral to successful implementation are presented.
Time frame: Up to 12 Months
Number of Staff Study Participants That Discussed Barriers for Feasibility Assessed Via SSIs
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the feasibility from the SSPs' perspective. The results for barriers that are integral to successful implementation are presented.
Time frame: Up to 12 Months
Change From Baseline in Implementation Leadership Scale (ILS) Score at Month 12
The ILS is a 12-item (facilitate implementation, obstacles, clear department standards, knowledge, ability to answer questions, awareness of concept, recognition, support employee efforts to learn, support employee efforts to use intervention, persevere(s) through the ups and downs, carries on through the challenges and reaction to criticial issues) measure that assesses SSP understanding of the degree to which leadership in their clinic/practice setting is proactive, knowledgeable, supportive, and perseverant with regards to implementing the CAB LA + RPV LA injection treatment in their settings. The items are measured on a five-point rating scale (1 = very great extent, 2 = great extent, 3 = moderate extent, 4 = slight extent, and 5 = not at all). The mean score ranges from 1 to 5. Higher the score means less understanding in leadership.
Time frame: Baseline (Month 1) and Month 12
Absolute Values of Implementation Climate Scale (ICS) Scores at Month 1 and Month 12
The ICS is a 9 item (team's main goals, importance of implementation, top priority, workshops, treatment training, training material, staff adaptability, flexibility, openness to new intervention) measure that assesses SSPs' perceptions of their team (i.e., the people that they work with) while using the CAB LA + RPV LA injection treatment in their clinic/practice setting. The items were measured on a five-point rating scale (1 = very great extent, 2 = great extent, 3 = moderate extent, 4 = slight extent, and 5 = not at all). The mean score ranges from 1 to 5. Higher the score means less seriousness for implementation in staff.
Time frame: Month 1 and Month 12
Number of Modifications Reported by SSPs Assessed Via FRAME-IS
The Framework for Reporting Adaptations and Modifications to Evidence-based interventions - Implementation Strategies (FRAME-IS) was a seven-question measure (contained both open and closed categorical questions) used to record details the modifications made to the implementation of the CAB LA + RPV LA injection treatment procedures.
Time frame: Month 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Number of Plan, Do, Study, Act (PDSA) Cycles Developed During the Continuous Quality Improvement (CQI) Calls Course
CQI were a 60 minutes calls involved working through a plan to address the identified barriers, optimize processes, and evaluate these efforts. This process of addressing barriers was guided by a series of Plan, Do, Study, Act (PDSA) cycles. Number of PDSA cycles developed are presented.
Time frame: Month 2 to Month 7
Number of Participants Spending Average Time in the Clinic/Practice for Each Injection Visit Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The average time was categorized as: Up to 20 Minutes, Up to 40 Minutes, Up to 60 Minutes, Up to 90 Minutes, More than 90 Minutes and missing. Missing include participants who did not provide a response for the question.
Time frame: Up to Month 12
Number of Participants Spending Average Time in an Exam Room Waiting for a Nurse (or Other Healthcare Provider) to Get the Injection Administered Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The average time was categorized as: Up to 10 Minutes, 11-20 Minutes, 21-30 Minutes, 31-45 Minutes, More than 45 Minutes and Missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants Rating Acceptability With the Amount of Time Spent in The Clinic/Practice for Each Injection Visit Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The rating of acceptability was categorized as extremely acceptable, very acceptable, somewhat acceptable, a little acceptable, not at all acceptable and missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants Rating Acceptability to Come to the Clinic/Practice Every 2 Months for the Injection Visit Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The rating of acceptability was categorized as extremely acceptable, very acceptable, somewhat acceptable, a little acceptable, not at all acceptable and missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants Taking Time Off From Work to Attend Appointment Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The time off responses were categorized as Whole day annual leave, Half day annual leave, Whole day sick leave, Half day sick leave, Whole day unpaid, Half day unpaid, Other, Not taken time off and missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants With Time it Took Them to Get to the Clinic Where They Receive HIV Treatment/Check-ups Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Up to 15 minutes, 16-30 minutes, 31-45 minutes, 46-60 minutes, More than 60 minutes, and missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants Who Seek Additional Care From a Dependent to Attend Appointment Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Yes, No, Not Applicable and Missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants That Endorsed Type of Transportation Used to Attend Appointments
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Taxi- Transportation service, Dropped-off, Private vehicle, Bicycle/scooter/ skateboard/ walked, Public transport and Missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants Taking Time Off From Work to Recover From Any Injection Site Reaction Issue Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The time off responses were categorized as No, Yes - On the day of receiving the treatment, Yes - One day after receiving the treatment, Yes-Two days after receiving the treatment, Yes-More than two days after receiving the treatment, Not Applicable, Missing and Missing Response for 'Yes'. Missing include participants who did not provide a response for the question. Missing Response for 'Yes' include participants who responded 'Yes' but did not provide duration of time off.
Time frame: Month 12
Number of Participants Rating Convenience of Clinic/Practice's Procedures for Scheduling Injections Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The convenience responses were categorized as Extremely convenient, Very convenient, Somewhat convenient, A little convenient, Not at all convenient, and Missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants Rating Convenience of Clinic/Practice's Procedures for Rescheduling Injections Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Extremely convenient, Very convenient, Somewhat convenient, A little convenient, Not at all convenient, Not applicable; I did not have to reschedule and Missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants Rating Feelings About Getting CAB+RPV Injection Treatment Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Extremely positive, Very positive, Somewhat positive, A little positive, Not at all positive and Missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants That Rated Perceived Knowledge About CAB+RPV Injection Treatment Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Extremely knowledgeable, Very knowledgeable, Somewhat knowledgeable, A little knowledgeable, Not at all knowledgeable and Missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants With Appointment Reminders Received Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question.The responses were categorized as Phone calls, Text/SMS messages, Existing clinic app, E-mail, Reminder in the mail, Another reminder and I did not receive reminders. The responses are not mutually exclusive.
Time frame: Month 12
Number of Participants Who Rated Helpfulness of Appointment Outside of Typical Work Times Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Extremely helpful, Very helpful, Somewhat helpful, A Little helpful, Not at all helpful and Missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants That Rated Agreement in Recommending the CAB+RPV Injections to Others Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Completely agree, Agree, Neutral, Disagree, Completely disagree and Missing. Missing include participants who did not provide a response for the question.
Time frame: Month 12
Number of Participants With Things Tried to Reduce Soreness Following Injections Assessed Via Questionnaire
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Take over-the-counter pain relievers, Use a hot compress, Use a cold compress, Avoid sitting for long periods of time, Light stretching and exercise, None of the above, Other and I don't get sore after my injections.
Time frame: Month 12
Number of PSPs That Discussed Facilitators for Acceptability Assessed Via Semi Structured Interviews (SSIs)
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed facilitators for acceptability are presented.
Time frame: Up to Month 12
Number of PSPs That Discussed Barriers for Acceptability Assessed Via SSIs
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed barriers for acceptability are presented.
Time frame: Up to Month 12
Number of PSPs That Discussed Facilitators for Appropriateness Assessed Via SSIs
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed facilitators for appropriateness are presented.
Time frame: Up to Month 12
Number of PSPs That Discussed Barriers for Appropriateness Assessed Via SSIs
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs with barriers for appropriateness are presented.
Time frame: Up to Month 12
Number of PSPs That Discussed Facilitators for Feasibility Assessed Via SSIs
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed facilitators for feasibility are presented.
Time frame: Up to Month 12
Number of PSPs That Discussed Barriers for Feasibility Assessed Via SSIs
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed barriers for feasibility are presented.
Time frame: Up to Month 12
Change From Baseline in Acceptability of Intervention Measure (AIM) Score in PSPs at Month 12
AIM assesses the acceptability of an intervention (i.e., perception among stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory). It is a four-item (1. The CAB+RPV injection treatment meets my approval for treating my HIV, 2. The CAB+RPV injection treatment is appealing to me, 3. I like the CAB+RPV injection treatment for my HIV, 4. I welcome the CAB+RPV injection treatment for my HIV) measure with a five-point rating scale, where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree. The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.
Time frame: Baseline (Month 1) and Month 12
Change From Baseline in Intervention Appropriateness Measure (IAM) Score in PSPs at Month 12
IAM assesses the appropriateness of an intervention (i.e., the perceived fit, relevance, or compatibility of the innovation for a given practice setting, provider, or consumer; and the perceived fit of the innovation to address a particular issue or problem). It is a four-item (1. The CAB+RPV injection treatment is fitting for my life, 2. The CAB+RPV injection treatment is suitable for my life, 3. The CAB+RPV injection treatment is applicable to my life, 4. The CAB+RPV injection treatment is a good match for my life) measure with a five-point rating scale, where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree. The mean score ranges from 1 to 5 with 1 indicating the least appropriateness and 5 the most appropriateness.
Time frame: Baseline (Month 1) and Month 12
Change From Baseline in Feasibility of Intervention Measure (FIM) Score in PSPs at Month 12
The four-item (1. The CAB+RPV injection treatment seems implementable in my life 2. The CAB+RPV injection treatment every 2 months is possible for me to use 3. The CAB+RPV injection treatment every 2 months seems doable in my life 4. The CAB+RPV injection treatment every 2 months seems easy to use in my life). FIM assesses perceived intervention feasibility. The items are measured on a five-point rating scale, where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree. The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.
Time frame: Baseline (Month 1) and Month 12
Associated Person Clinical Sustainability Assessment Tool (APCSAT) Average Domain Score at Month 12
The APCSAT is a 35-item measure that assesses SSP impressions of the data in their clinic. Sustainability refers to the ability to maintain and expand the CAB LA + RPV LA injection treatment and its benefits over time. SSPs were asked to rate their clinic/practice along a range of specific domains that affect sustainability, including: 'Engages Staff \& Leadership,' 'Engaging Stakeholders,' 'Monitoring and Evaluation,' 'Implementation \& Training,' 'Outcomes \& Effectiveness,' 'Workflow Integration,' and 'Organizational Readiness.' Five items were presented to SSPs in each section. The items were measured on a seven-point rating scale (1 = little to no extent to 7 = to a very great extent. Domain total was divided by the total number of items with a score to get average score.
Time frame: Month 12
Percentage of PSP Receiving Injections Within Target Window
The target window for participants to receive injection was from Day -7 to Day 7.
Time frame: Day -7 to Day 7 of Month 2, 4, 6, 8, 10 and 12
Percentage of PSPs With Plasma HIV-1 Ribonucleic Acid (RNA) Less Than (<)50 Copies Per Milliliter (c/ml)
Plasma samples were collected from the participant at specific time points.
Time frame: Month 1, 2, 4, 8 and 12
Number of Participants With Confirmed Virologic Failure (CVF) Over Time
CVF was defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/ml.
Time frame: Month 1, 2, 4, 8, 10 and 12
Number of PSPs With Adverse Events (AEs) And Serious AEs (SAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.
Time frame: Up to 12 Months
Number of PSPs Discontinuing Treatment Due to AEs
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
Time frame: Up to 12 Months
Number of PSP With Preference for Therapy Assessed Via Preference Questionnaire
PSPs were asked to think about their experience of using the long-acting injectable medication versus the daily oral HIV medication, and to select their preferred treatment and all the reasons that support their preference. Results are categorized as: 'long-acting injectable HIV medication', 'daily oral HIV medication', 'no preference', Missing and Erroneous. Missing include participants who did not provide a response for the question. PSPs who completed this question incorrectly (i.e., checked reasons without a ticking a leading preference or checked more than one leading preference box) were included in Erroneous.
Time frame: Up to 12 Months
A total of 437 patient study participants (PSPs) \[people living with HIV\] were enrolled. 430 PSP received study treatment and were included in the safety population. Staff Study Participants (SSP) (HIV care providers, nurses/staff performing injections administrators/clinic managers) were not counted as enrolled. SSP were randomized based on implementation strategy - Enhanced (Arm-E) and Standard (Arm -S).
| Milestone | Patient Study Participants |
|---|---|
| Started | 430 |
| Completed | 402 |
| Not completed | 28 |
| Withdrew: Adverse event | 15 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Physician decision | 3 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Protocol deviation | 2 |
The AIM-Imp was designed to assess the acceptability of an implementation process (i.e., perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory). The measure consists of four items/statements (1. The implementation support thus far meets my approval 2. The implementation support thus far is appealing to me 3. I like the implementation support I have received 4. I welcome implementation support for the CAB + RPV injection treatment), each with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.
| Scores on a scale | Staff Study Participants - Enhanced Implementation Arm | Staff Study Participants - Standard Implementation Arm |
|---|---|---|
| Baseline (Month 1) | 3.8 ± 0.76 | 3.9 ± 0.75 |
| Month 12 | 0.28 ± 0.828 | 0.33 ± 0.666 |
The IAM-Imp is designed to assess the appropriateness of an implementation process (i.e., the perceived fit, relevance, or compatibility of the innovation for a given practice setting, provider, or consumer, and the perceived fit of the innovation to address a particular issue or problem). The IAM-Imp is a four-item/statement measure (1. The implementation support thus far seems fitting 2. The implementation support seems suitable for using the CAB + RPV injection treatment 3. The implementation support seems applicable for the CAB + RPV injection treatment 4. The implementation support seems like a good match) with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least appropriateness and 5 the most appropriateness.
| Scores on a scale | Staff Study Participants-Enhanced Implementation Arm | Staff Study Participants - Standard Implementation Arm |
|---|---|---|
| Baseline (Month 1) | 3.8 ± 0.78 | 3.9 ± 0.78 |
| Month 12 | 0.22 ± 0.740 | 0.31 ± 0.729 |
The FIM-Imp was a four-item/statement measure (1. The implementation support seems implementable in our clinic/practice 2. The implementation support seems possible in our clinic/practice 3. The implementation support seems doable in our clinic/practice 4. The implementation support seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.
| Scores on a scale | Staff Study Participants - Enhanced Implementation Arm | Staff Study Participants - Standard Implementation Arm |
|---|---|---|
| Baseline (Month 1) | 4.0 ± 0.66 | 4.0 ± 0.64 |
| Month 12 | 0.06 ± 1.047 | 0.34 ± 0.773 |
A semi-structured interview guide was designed to support the discussion surrounding experience with the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the acceptability from the SSPs' perspective. The results for facilitators that are integral to successful implementation are presented.
| Participants | Staff Study Participants - Standard Implementation Arm | Staff Study Participants - Enhanced Implementation Arm |
|---|---|---|
| Improved Patient's Quality of Life | 0 | 1 |
| Injection pain management | 2 | 0 |
| No commute to clinic | 1 | 3 |
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the acceptability from the SSPs' perspective. The results for barriers that are integral to successful implementation are presented.
| Participants | Staff Study Participants - Standard Implementation Arm | Staff Study Participants - Enhanced Implementation Arm |
|---|---|---|
| Number of Staff Study Participants That Discussed Barriers for Acceptability Assessed Via SSIs | 1 | 1 |
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the appropriateness from the SSPs' perspective. The results for facilitators that are integral to successful implementation are presented.
| Participants | Staff Study Participants - Standard Implementation Arm | Staff Study Participants - Enhanced Implementation Arm |
|---|---|---|
| Patient characteristics | 1 | 2 |
| Patient selection | 0 | 2 |
| Hours of home visit | 1 | 1 |
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the appropriateness from the SSPs' perspective. The results for barriers that are integral to successful implementation are presented.
| Participants | Staff Study Participants - Standard Implementation Arm | Staff Study Participants - Enhanced Implementation Arm |
|---|---|---|
| Number of Staff Study Participants That Discussed Barriers for Appropriateness Assessed Via SSIs | 0 | 0 |
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the feasibility from the SSPs' perspective. The results for facilitators that are integral to successful implementation are presented.
| Participants | Staff Study Participants - Standard Implementation Arm | Staff Study Participants - Enhanced Implementation Arm |
|---|---|---|
| Clinic or unit characteristics (e.g., autonomy, size, flexibility) | 2 | 3 |
| Experience with the medication | 0 | 1 |
| Implementation processes | 2 | 2 |
| Medication storage | 2 | 1 |
| Number of patients | 1 | 2 |
| Nursing staff in consultation department | 0 | 1 |
| Pharmacy flexibility | 0 | 1 |
| Room/space characteristics | 1 | 1 |
| Staff availability | 0 | 2 |
| Staff characteristics (e.g., experience, qualification, motivation) | 6 | 8 |
| Training | 1 | 0 |
| ViiV support and materials | 3 | 1 |
A semi-structured interview guide was designed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the feasibility from the SSPs' perspective. The results for barriers that are integral to successful implementation are presented.
| Participants | Staff Study Participants - Standard Implementation Arm | Staff Study Participants - Enhanced Implementation Arm |
|---|---|---|
| Number of Staff Study Participants That Discussed Barriers for Feasibility Assessed Via SSIs | 0 | 0 |
The ILS is a 12-item (facilitate implementation, obstacles, clear department standards, knowledge, ability to answer questions, awareness of concept, recognition, support employee efforts to learn, support employee efforts to use intervention, persevere(s) through the ups and downs, carries on through the challenges and reaction to criticial issues) measure that assesses SSP understanding of the degree to which leadership in their clinic/practice setting is proactive, knowledgeable, supportive, and perseverant with regards to implementing the CAB LA + RPV LA injection treatment in their settings. The items are measured on a five-point rating scale (1 = very great extent, 2 = great extent, 3 = moderate extent, 4 = slight extent, and 5 = not at all). The mean score ranges from 1 to 5. Higher the score means less understanding in leadership.
| Scores on a scale | Staff Study Participants - Enhanced Implementation Arm | Staff Study Participants - Standard Implementation Arm |
|---|---|---|
| Baseline (Month 1) | 2.3 ± 0.86 | 2.0 ± 0.81 |
| Month 12 | -0.1 ± 1.19 | 0.2 ± 0.51 |
The ICS is a 9 item (team's main goals, importance of implementation, top priority, workshops, treatment training, training material, staff adaptability, flexibility, openness to new intervention) measure that assesses SSPs' perceptions of their team (i.e., the people that they work with) while using the CAB LA + RPV LA injection treatment in their clinic/practice setting. The items were measured on a five-point rating scale (1 = very great extent, 2 = great extent, 3 = moderate extent, 4 = slight extent, and 5 = not at all). The mean score ranges from 1 to 5. Higher the score means less seriousness for implementation in staff.
| Scores on a scale | Staff Study Participants - Enhanced Implementation Arm | Staff Study Participants - Standard Implementation Arm |
|---|---|---|
| Month 1 | 2.5 ± 0.65 | 2.8 ± 0.80 |
| Month 12 | 2.7 ± 0.72 | 2.6 ± 0.80 |
The Framework for Reporting Adaptations and Modifications to Evidence-based interventions - Implementation Strategies (FRAME-IS) was a seven-question measure (contained both open and closed categorical questions) used to record details the modifications made to the implementation of the CAB LA + RPV LA injection treatment procedures.
| Number of Modifications | Staff Study Participants - Enhanced Implementation Arm | Staff Study Participants - Standard Implementation Arm |
|---|---|---|
| Month 2 | 15 | 7 |
| Month 3 | 10 | 2 |
| Month 4 | 5 | 2 |
| Month 5 | 1 | 1 |
| Month 6 | 3 | 0 |
| Month 7 | 4 | 0 |
| Month 8 | 0 | 0 |
| Month 9 | 3 | 0 |
| Month 10 | 0 | 0 |
| Month 11 | 3 | 1 |
| Month 12 | 0 | 1 |
CQI were a 60 minutes calls involved working through a plan to address the identified barriers, optimize processes, and evaluate these efforts. This process of addressing barriers was guided by a series of Plan, Do, Study, Act (PDSA) cycles. Number of PDSA cycles developed are presented.
| Cycles | Staff Study Participants (SSP) |
|---|---|
| Number of Plan, Do, Study, Act (PDSA) Cycles Developed During the Continuous Quality Improvement (CQI) Calls Course | 23 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The average time was categorized as: Up to 20 Minutes, Up to 40 Minutes, Up to 60 Minutes, Up to 90 Minutes, More than 90 Minutes and missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Up to 20 Minutes | 71 |
| Up to 40 Minutes | 134 |
| Up to 60 Minutes | 99 |
| Up to 90 Minutes | 48 |
| More than 90 Minutes | 19 |
| Missing | 8 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The average time was categorized as: Up to 10 Minutes, 11-20 Minutes, 21-30 Minutes, 31-45 Minutes, More than 45 Minutes and Missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Up to 10 Minutes | 190 |
| 11-20 Minutes | 100 |
| 21-30 Minutes | 54 |
| 31-45 Minutes | 25 |
| More than 45 Minutes | 5 |
| Missing | 5 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The rating of acceptability was categorized as extremely acceptable, very acceptable, somewhat acceptable, a little acceptable, not at all acceptable and missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Extremely acceptable | 140 |
| Very acceptable | 151 |
| Somewhat acceptable | 72 |
| A little acceptable | 11 |
| Not at all acceptable | 0 |
| Missing | 5 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The rating of acceptability was categorized as extremely acceptable, very acceptable, somewhat acceptable, a little acceptable, not at all acceptable and missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Extremely acceptable | 163 |
| Very acceptable | 154 |
| Somewhat acceptable | 51 |
| A little acceptable | 6 |
| Not at all acceptable | 0 |
| Missing | 5 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The time off responses were categorized as Whole day annual leave, Half day annual leave, Whole day sick leave, Half day sick leave, Whole day unpaid, Half day unpaid, Other, Not taken time off and missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Whole day annual leave | 27 |
| Half day annual leave | 20 |
| Whole day sick leave | 5 |
| Half day sick leave | 3 |
| Whole day unpaid | 9 |
| Half day unpaid | 20 |
| Other | 64 |
| Not taken Time Off | 222 |
| Missing | 9 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Up to 15 minutes, 16-30 minutes, 31-45 minutes, 46-60 minutes, More than 60 minutes, and missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Up to 15 minutes | 66 |
| 16-30 minutes | 138 |
| 31-45 minutes | 87 |
| 46-60 minutes | 44 |
| More than 60 minutes | 39 |
| Missing | 5 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Yes, No, Not Applicable and Missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Yes | 16 |
| No | 318 |
| Not Applicable | 39 |
| Missing | 6 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Taxi- Transportation service, Dropped-off, Private vehicle, Bicycle/scooter/ skateboard/ walked, Public transport and Missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Taxi-Transportation service | 13 |
| Dropped-off | 12 |
| Private vehicle | 164 |
| Bicycle/ scooter/ skateboard/ walked | 49 |
| Public transport | 138 |
| Missing | 3 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The time off responses were categorized as No, Yes - On the day of receiving the treatment, Yes - One day after receiving the treatment, Yes-Two days after receiving the treatment, Yes-More than two days after receiving the treatment, Not Applicable, Missing and Missing Response for 'Yes'. Missing include participants who did not provide a response for the question. Missing Response for 'Yes' include participants who responded 'Yes' but did not provide duration of time off.
| Participants | Patient Study Participants |
|---|---|
| No | 294 |
| Yes, on the day of receiving the treatment | 45 |
| Yes, one day after receiving the treatment | 9 |
| Yes, two days after receiving the treatment | 7 |
| Yes, more than two days after receiving the treatment | 5 |
| Not Applicable | 16 |
| Missing | 5 |
| Missing response for 'Yes' | 2 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The convenience responses were categorized as Extremely convenient, Very convenient, Somewhat convenient, A little convenient, Not at all convenient, and Missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Extremely convenient | 175 |
| Very convenient | 154 |
| Somewhat convenient | 43 |
| A little convenient | 4 |
| Not at all convenient | 0 |
| Missing | 3 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Extremely convenient, Very convenient, Somewhat convenient, A little convenient, Not at all convenient, Not applicable; I did not have to reschedule and Missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Extremely convenient | 158 |
| Very convenient | 153 |
| Somewhat convenient | 25 |
| A little convenient | 2 |
| Not at all convenient | 0 |
| Not applicable; I did not have to schedule | 39 |
| Missing | 2 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Extremely positive, Very positive, Somewhat positive, A little positive, Not at all positive and Missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Extremely positive | 234 |
| Very positive | 112 |
| Somewhat positive | 23 |
| A little positive | 4 |
| Not at all positive | 0 |
| Missing | 6 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Extremely knowledgeable, Very knowledgeable, Somewhat knowledgeable, A little knowledgeable, Not at all knowledgeable and Missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Extremely knowledgeable | 124 |
| Very knowledgeable | 188 |
| Somewhat knowledgeable | 57 |
| A little knowledgeable | 6 |
| Not at all knowledgeable | 0 |
| Missing | 4 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question.The responses were categorized as Phone calls, Text/SMS messages, Existing clinic app, E-mail, Reminder in the mail, Another reminder and I did not receive reminders. The responses are not mutually exclusive.
| Participants | Patient Study Participants |
|---|---|
| Phone calls | 80 |
| Text/SMS messages | 275 |
| Existing clinic app | 48 |
| 161 | |
| Reminder in the mail | 21 |
| Another reminder | 3 |
| I did not receive reminders | 14 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Extremely helpful, Very helpful, Somewhat helpful, A Little helpful, Not at all helpful and Missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Extremely helpful | 135 |
| Very helpful | 123 |
| Somewhat helpful | 50 |
| A Little helpful | 38 |
| Not at all helpful | 28 |
| Missing | 5 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Completely agree, Agree, Neutral, Disagree, Completely disagree and Missing. Missing include participants who did not provide a response for the question.
| Participants | Patient Study Participants |
|---|---|
| Completely agree | 283 |
| Agree | 75 |
| Neutral | 15 |
| Disagree | 1 |
| Completely disagree | 1 |
| Missing | 4 |
Study-specific questions were developed to gather data on the facilitators and barriers of the CAB LA + RPV LA injection treatment. The response options are different for each question. The responses were categorized as Take over-the-counter pain relievers, Use a hot compress, Use a cold compress, Avoid sitting for long periods of time, Light stretching and exercise, None of the above, Other and I don't get sore after my injections.
| Participants | Patient Study Participants |
|---|---|
| Take over-the-counter pain relievers | 139 |
| Use a hot compress | 20 |
| Use a cold compress | 19 |
| Avoid sitting for long periods of time | 87 |
| Light stretching and exercise | 71 |
| None of the above | 61 |
| Other | 31 |
| I don't get sore after my injections | 72 |
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed facilitators for acceptability are presented.
| Participants | Patient Study Participants |
|---|---|
| Feeling informed about CAB+RPV LA injection | 105 |
| Overall positive experience with CAB+RPV LA | 100 |
| Acceptable overall experience at clinic | 82 |
| In-person communication with HCP | 76 |
| Not thinking and/or worrying about taking medication | 66 |
| Experienced injector | 64 |
| Acceptable clinic hours to receive CAB+RPV LA injections | 51 |
| CAB+RPV LA injection experience met expectations | 43 |
| Patient travel facilitation | 33 |
| CAB+RPV LA injection experience better than expected | 32 |
| Staff responsiveness | 34 |
| Number of visits | 30 |
| Satisfaction with rescheduling process | 29 |
| Distance to clinic | 27 |
| Not being reminded about HIV | 26 |
| Acceptable time spent in clinic | 25 |
| Treatment adherence | 24 |
| Gaining a sense of freedom | 24 |
| Discreet treatment | 23 |
| Communication with staff | 22 |
| Reduced stigma due to CAB+RPV LA injection | 22 |
| Reduction in injection pain | 20 |
| [Patient-perspective] Medication for injection pain management | 19 |
| Reduced stress or worry due to CAB+RPV LA injection | 19 |
| HCP advice on pain management | 18 |
| [Patient-perspective] Activities to avoid for injection pain management | 16 |
| Website and/or internet | 15 |
| Characteristics of HCP communication | 14 |
| Written materials and brochures | 14 |
| Study materials | 14 |
| Time of informing | 13 |
| Medication collection, storage and/or preparation | 12 |
| Fewer side effects | 12 |
| Time-saving approach | 12 |
| [Patient-perspective] Activities to do for injection pain management | 11 |
| Administration in other clinical setting | 11 |
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed barriers for acceptability are presented.
| Participants | Patient Study Participants |
|---|---|
| Injection side effects including pain (Topic - Treatment Components Difficult for PSP) | 67 |
| Injection side effects including pain (Topic-Experienced Challenges to Receive CAB+PRV LA Injection) | 33 |
| CAB+RPV LA injection experience worse than expected | 11 |
| Waiting time | 11 |
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed facilitators for appropriateness are presented.
| Participants | Patient Study Participants |
|---|---|
| Number of PSPs That Discussed Facilitators for Appropriateness Assessed Via SSIs | 0 |
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs with barriers for appropriateness are presented.
| Participants | Patient Study Participants |
|---|---|
| Patient fearing or squeamish about injections | 22 |
| Patients not tolerating intramuscular injection | 12 |
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed facilitators for feasibility are presented.
| Participants | Patient Study Participants |
|---|---|
| Person to contact during CARISEL study | 102 |
| [Patient-perspective] Calendar, Diary, Notes and/or Reminders | 69 |
| No missed appointment and/or rescheduling | 65 |
| Target date explained | 57 |
| Easy to contact | 57 |
| Contacting clinic staff during CARISEL study | 52 |
| Home administration by HCP | 41 |
| No issues due to transportation and/or parking | 37 |
| No challenges to receive CAB+RPV LA injection | 33 |
| Not contacting clinic staff during CARISEL study | 31 |
| No issues due to work | 28 |
| Clinic Reminder [all types] | 27 |
| Term of target date helpful | 25 |
| [Patient-perspective] Setting reminders | 23 |
| CAB+RPV LA administration at GP office | 22 |
| CAB+RPV LA administration at nurse office and/or healthcare centers | 19 |
| No issues to attend visits due to childcare or family commitments | 16 |
| [Patient-perspective] Arrangements at work | 16 |
| Clinic reminder: Text and/or SMS | 14 |
| [Patient-perspective] Appointment scheduling strategies | 14 |
| No issues due to clinic hours | 13 |
A semi-structured interview guide was developed to support the discussion surrounding experience with for the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the Acceptability, Appropriateness, Feasibility, and Sustainability from the PSPs' perspective. Results of number of PSPs that discussed barriers for feasibility are presented.
| Participants | Patient Study Participants |
|---|---|
| Target date not explained | 38 |
| Missed appointment and/or rescheduling | 23 |
| Issues due to work | 21 |
| Issues due to transportation and/or parking | 14 |
AIM assesses the acceptability of an intervention (i.e., perception among stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory). It is a four-item (1. The CAB+RPV injection treatment meets my approval for treating my HIV, 2. The CAB+RPV injection treatment is appealing to me, 3. I like the CAB+RPV injection treatment for my HIV, 4. I welcome the CAB+RPV injection treatment for my HIV) measure with a five-point rating scale, where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree. The mean score ranges from 1 to 5 with 1 indicating the least acceptability and 5 the most acceptability.
| Scores on a scale | Patient Study Participants |
|---|---|
| Baseline (Month 1) | 4.55 ± 0.666 |
| Month 12 | 0.10 ± 0.834 |
IAM assesses the appropriateness of an intervention (i.e., the perceived fit, relevance, or compatibility of the innovation for a given practice setting, provider, or consumer; and the perceived fit of the innovation to address a particular issue or problem). It is a four-item (1. The CAB+RPV injection treatment is fitting for my life, 2. The CAB+RPV injection treatment is suitable for my life, 3. The CAB+RPV injection treatment is applicable to my life, 4. The CAB+RPV injection treatment is a good match for my life) measure with a five-point rating scale, where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree. The mean score ranges from 1 to 5 with 1 indicating the least appropriateness and 5 the most appropriateness.
| Scores on a scale | Patient Study Participants |
|---|---|
| Baseline (Month 1) | 4.47 ± 0.762 |
| Month 12 | 0.13 ± 0.928 |
The four-item (1. The CAB+RPV injection treatment seems implementable in my life 2. The CAB+RPV injection treatment every 2 months is possible for me to use 3. The CAB+RPV injection treatment every 2 months seems doable in my life 4. The CAB+RPV injection treatment every 2 months seems easy to use in my life). FIM assesses perceived intervention feasibility. The items are measured on a five-point rating scale, where 1=completely disagree, 2=disagree, 3=neither agree nor disagree, 4=agree, and 5=completely agree. The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility.
| Scores on a scale | Patient Study Participants |
|---|---|
| Baseline (Month 1) | 4.51 ± 0.672 |
| Month 12 | 0.07 ± 0.857 |
The APCSAT is a 35-item measure that assesses SSP impressions of the data in their clinic. Sustainability refers to the ability to maintain and expand the CAB LA + RPV LA injection treatment and its benefits over time. SSPs were asked to rate their clinic/practice along a range of specific domains that affect sustainability, including: 'Engages Staff \& Leadership,' 'Engaging Stakeholders,' 'Monitoring and Evaluation,' 'Implementation \& Training,' 'Outcomes \& Effectiveness,' 'Workflow Integration,' and 'Organizational Readiness.' Five items were presented to SSPs in each section. The items were measured on a seven-point rating scale (1 = little to no extent to 7 = to a very great extent. Domain total was divided by the total number of items with a score to get average score.
| Scores on a scale | Staff Study Participants - Enhanced Implementation Arm | Staff Study Participants - Standard Implementation Arm |
|---|---|---|
| Engages Staff & Leadership | 5.57 ± 0.72 | 5.58 ± 0.49 |
| Engaging Stakeholders | 5.00 ± 1.06 | 5.05 ± 0.79 |
| Monitoring and Evaluation | 5.37 ± 0.16 | 5.49 ± 0.11 |
| Implementation & Training | 5.62 ± 0.56 | 5.56 ± 0.43 |
| Outcomes & Effectiveness | 5.39 ± 0.70 | 5.41 ± 0.69 |
| Workflow Integration | 5.46 ± 0.35 | 5.23 ± 0.34 |
| Organizational Readiness | 5.30 ± 0.32 | 5.05 ± 0.36 |
The target window for participants to receive injection was from Day -7 to Day 7.
| Percentage of Participants | Patient Study Participants |
|---|---|
| Month 2 | 99 |
| Month 4 | 93 |
| Month 6 | 91 |
| Month 8 | 91 |
| Month 10 | 94 |
| Month 12 | 91 |
Plasma samples were collected from the participant at specific time points.
| Percentage of Participants | Patient Study Participants |
|---|---|
| Month 1 | 99 (97.0 to 99.5) |
| Month 2 | 96 (93.7 to 97.7) |
| Month 4 | 93 (90.5 to 95.4) |
| Month 8 | 86 (82.7 to 89.4) |
| Month 12 | 87 (83.2 to 89.8) |
CVF was defined as rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/ml.
| Participants | Patient Study Participants |
|---|---|
| Month 1 | 0 |
| Month 2 | 0 |
| Month 4 | 0 |
| Month 6 | 0 |
| Month 8 | 0 |
| Month 10 | 1 |
| Month 12 | 0 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose may result in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity or is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function.
| Participants | Patient Study Participants |
|---|---|
| Any AEs | 420 |
| Any SAEs | 15 |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
| Participants | Patient Study Participants |
|---|---|
| Number of PSPs Discontinuing Treatment Due to AEs | 2 |
PSPs were asked to think about their experience of using the long-acting injectable medication versus the daily oral HIV medication, and to select their preferred treatment and all the reasons that support their preference. Results are categorized as: 'long-acting injectable HIV medication', 'daily oral HIV medication', 'no preference', Missing and Erroneous. Missing include participants who did not provide a response for the question. PSPs who completed this question incorrectly (i.e., checked reasons without a ticking a leading preference or checked more than one leading preference box) were included in Erroneous.
| Participants | Patient Study Participants |
|---|---|
| Daily oral HIV medication | 2 |
| Long-acting injectable HIV medication | 275 |
| No preference | 0 |
| Missing | 2 |
| Erroneous | 100 |
A semi-structured interview guide was designed to support the discussion surrounding experience with the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the acceptability from the SSPs' perspective. The results of themes that are integral to successful implementation are presented based on implementation strategies.
| Participants | Staff Study Participants - Standard Implementation Arm | Staff Study Participants - Enhanced Implementation Arm |
|---|---|---|
| Positive opinion about CAB+RPV LA | 28 | 28 |
| Negative opinion about CAB+RPV LA | 0 | 0 |
| Ambivalent opinion about CAB+RPV LA | 3 | 1 |
| Opinion about CAB+RPV LA did not change | 15 | 14 |
| Opinion about CAB+RPV LA changed | 9 | 11 |
| Treatment and/or its implementation is better than expected | 7 | 11 |
| Treatment and/or its implementation is worse than expected | 2 | 0 |
| Implementation facilitators reported | 16 | 19 |
| Did NOT encounter resistance to using CAB+RPV LA | 8 | 19 |
| ADMINISTRATION OUTSIDE CLINIC: Other clinical settings | 15 | 15 |
| ADMINISTRATION OUTSIDE CLINIC: Self-administered | 20 | 23 |
| What would do differently | 2 | 4 |
A semi-structured interview guide was designed to support the discussion surrounding experience with the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the appropriateness from the SSPs' perspective. The results of themes that are integral to successful implementation are presented based on implementation strategies.
| Participants | Staff Study Participants - Standard Implementation Arm | Staff Study Participants - Enhanced Implementation Arm |
|---|---|---|
| Implementation facilitators reported | 16 | 19 |
| ADMINISTRATION OUTSIDE CLINIC: Home administration by HCP | 24 | 19 |
| What would do differently | 2 | 4 |
| Recommended strategies to support patient adherence | 20 | 22 |
A semi-structured interview guide was designed to support the discussion surrounding experience with the implementation of CAB+RPV LA injection treatment. The interview guide topics were informed by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and Proctor Outcomes to facilitate discussions on the feasibility from the SSPs' perspective. The results of themes that are integral to successful implementation are presented based on implementation strategies.
| Participants | Staff Study Participants - Standard Implementation Arm | Staff Study Participants - Enhanced Implementation Arm |
|---|---|---|
| No changes made to accommodate clinic needs | 10 | 7 |
| Changes made to accommodate clinic needs | 22 | 22 |
| Implementation facilitators reported | 16 | 19 |
| Developed supplemental materials for implementation | 3 | 5 |
| Staffing and workload issues was not a challenge | 12 | 7 |
| Staffing and workload issues was a challenge | 18 | 14 |
| Staffing and workload issues: How tried to/overcame this challenge | 7 | 10 |
| Staffing and workload issues: Still a challenge | 7 | 4 |
| Staffing and workload issues: Not a challenge at present | 8 | 5 |
| Availability of rooms and designated space: Was not a challenge | 19 | 15 |
| Availability of rooms and designated space: Was a challenge | 13 | 7 |
| Availability of rooms and designated space: How overcame this challenge | 9 | 7 |
| Availability of rooms and designated space: Still a challenge | 8 | 4 |
| Availability of rooms and designated space: Not a challenge at present | 4 | 3 |
| Coordination between the clinic and pharmacy: Was not a challenge | 23 | 17 |
| Coordination between the clinic and pharmacy: Was a challenge | 4 | 9 |
| Coordination between the clinic and pharmacy: How overcame this challenge | 3 | 6 |
| Coordination between the clinic and pharmacy: Still a challenge | 3 | 3 |
| Coordination between the clinic and pharmacy: Not a challenge at present | 0 | 4 |
| Medication supply and storage: Was not a challenge | 16 | 15 |
| Medication supply and storage: Was a challenge | 9 | 3 |
| Medication supply and storage: How tried to/overcame this challenge | 7 | 2 |
| Medication supply and storage: Still a challenge | 2 | 1 |
| Medication supply and storage: Not a challenge at present | 5 | 2 |
| Being able to administer injections: Was not a challenge | 24 | 17 |
| Being able to administer injections: Was a challenge | 3 | 3 |
| Being able to administer injections: How overcame this challenge | 1 | 3 |
| Being able to administer injections: Still a challenge | 1 | 2 |
| Being able to administer injections: Not a challenge at present | 2 | 1 |
| Being able to administer injections: ViiV not supportive of CAB+RPV LA implementation | 0 | 5 |
| Being able to administer injections: ViiV supportive of CAB+RPV LA implementation | 31 | 23 |
| Being able to administer injections: What would do differently | 2 | 4 |
Collected over Serious adverse events (SAEs), non-serious AEs and all-cause mortality were collected up to Month 26.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patient Study Participants | 0/430 (0%) | 17/430 (4%) | 384/430 (89.3%) |
| Event | Patient Study Participants |
|---|---|
| AppendicitisInfections and infestations | 1/430 |
| COVID-19Infections and infestations | 1/430 |
| PeritonitisInfections and infestations | 1/430 |
| Yersinia infectionInfections and infestations | 1/430 |
| Abdominal painGastrointestinal disorders | 1/430 |
| Appendicitis noninfectiveGastrointestinal disorders | 1/430 |
| Clavicle fractureInjury, poisoning and procedural complications | 1/430 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/430 |
| Subdural haemorrhageInjury, poisoning and procedural complications | 1/430 |
| Major depressionPsychiatric disorders | 1/430 |
| Event | Patient Study Participants |
|---|---|
| Injection site painGeneral disorders | 345/430 |
| COVID-19Infections and infestations | 79/430 |
| Injection site indurationGeneral disorders | 48/430 |
| PyrexiaGeneral disorders | 41/430 |
| HeadacheNervous system disorders | 41/430 |
| Injection site discomfortGeneral disorders | 38/430 |
| Back painMusculoskeletal and connective tissue disorders | 35/430 |
| Injection site noduleGeneral disorders | 32/430 |
| NasopharyngitisInfections and infestations | 30/430 |
| DiarrhoeaGastrointestinal disorders | 30/430 |
| Age, Continuous(Years) | Patient Study Participants |
|---|---|
| Mean | 44.2 ± 10.13 |
| Sex: Female, Male(Participants) | Patient Study Participants |
|---|---|
| Female | 115 |
| Male | 315 |
| Race/Ethnicity, Customized(Participants) | Patient Study Participants |
|---|---|
| American Indian Or Alaska Native | 7 |
| Asian | 9 |
| Black Or African American | 76 |
| White | 336 |
| Multiple | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Sep 2020 to primary completion in Mar 2022, 17 months.
Results were first posted in May 2023, 1 year 2 months after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 17 months is below that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cabotegravir